Northern Trust 13F: Adds $25M to ARWR Stake
Northern Trust increased its holdings in Arrowhead Pharmaceuticals by 23% in its latest SEC filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Northern Trust added 309,580 shares to its stake in Arrowhead Pharmaceuticals, Inc. ($ARWR), a 23% increase, according to a 13F filing with the SEC dated May 14, 2026. It reported 1,655,837 shares worth $132.30 million at the end of the quarter.
Since the filing, $ARWR is down 5.2% after 1 week, down 3.2% after 1 month and down 29.9% to date (from the $79.69 close on May 14, 2026).
ARWR
Arrowhead Pharmaceuticals, Inc.
Key Points
- Northern Trust increased its position in Arrowhead Pharmaceuticals by 23%, adding 309,580 shares for a total of 1,655,837 shares worth $135.5 million.
- Arrowhead Pharmaceuticals, trading at $81.82, has a market cap of $11.5 billion with a forward P/E ratio of -18.85 and a beta of 1.275.
- Analysts such as RBC Capital and JP Morgan have set buy ratings, with price targets ranging from $46 to $110.
Get $ARWR trade alerts by text
We text you when insiders, Congress or big funds trade $ARWR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Arrowhead Pharmaceuticals, Inc. alert may contain errors. Disclosures
Northern Trust recently boosted its stake in Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR) by 23%. According to its latest SEC filing, the firm added 309,580 shares, bringing its total holdings to 1,655,837 shares, valued at approximately $135.5 million as of the reporting period.
Northern Trust vs. the S&P 500
Hypothetical returns from Northern Trust's disclosed trades, not real profit or advice. How we model this.
What Changed in Northern Trust's Arrowhead Pharmaceuticals Position
Northern Trust significantly increased its investment in Arrowhead Pharmaceuticals, raising its holdings by 309,580 shares to a total of 1,655,837 shares. This represents a 23% increase in its stake, highlighting a substantial commitment to the biotechnology firm.
Other Institutional Activity in Arrowhead Pharmaceuticals
Other major institutional investors also made notable moves with Arrowhead Pharmaceuticals. BlackRock, Inc. reduced its stake by 3,157,063 shares, ending with 18,161,519 shares valued at about $1.14 billion. Avoro Capital Advisors LLC slightly increased its position by 74,999 shares, totaling 10,699,999 shares worth approximately $670.9 million. FMR LLC added 746,244 shares, bringing its holdings to 7,266,652 shares valued at $455.6 million. Meanwhile, Vanguard Portfolio Management LLC established a new position with 7,146,136 shares valued at $448.1 million.
Arrowhead Pharmaceuticals, Inc. Stock Up 20.2%
Shares of Arrowhead Pharmaceuticals are currently trading around $81.82. The company holds a market cap of approximately $11.5 billion. Despite not being profitable, as indicated by its negative forward P/E ratio of -18.85, the stock has shown volatility with a beta of 1.275. Over the past year, the stock has traded between $14.30 and $84.55, with moving averages of $74.14 for 50 days and $58.12 for 200 days.
Recent Earnings
Arrowhead Pharmaceuticals reported revenues of $622 million, though it experienced a revenue decline of 86.4%. The company posted a net margin of -48.38% and a return on equity of -42.37%. Its next earnings report is scheduled for August 6, 2026.
Insider Buying and Selling at Arrowhead Pharmaceuticals, Inc.
Recent insider transactions include Matthew Gregory Cohen purchasing 11,882 shares on June 15, 2026. Conversely, Hongbo Lu sold 2,970 shares on May 12 under a planned sale at an average price of $76.88. James Hamilton, the Chief Medical Officer, sold shares on multiple occasions, including 10,000 shares on April 23 at $75.00.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for Arrowhead Pharmaceuticals. On June 17, 2026, Leerink Partners maintained a hold rating with a $72 target. Bernstein also maintained a hold rating with a $46 target on May 13. RBC Capital and JP Morgan both issued buy ratings, with price targets of $87 and $88, respectively.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is a biotechnology company based in Pasadena, California. Led by CEO Dr. Christopher R. Anzalone, the company focuses on developing medicines for treating intractable diseases. Its pipeline includes several RNAi therapeutics in various stages of clinical trials. Arrowhead collaborates with major pharmaceutical firms like GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics.
Bottom Line
Northern Trust's increased position in Arrowhead Pharmaceuticals signifies confidence in the company's potential. Investors keep a close eye on such 13F filings to gauge institutional sentiment, though these filings are retrospective and may not reflect current positions. With analysts showing varied ratings, Arrowhead remains a stock to watch in the biotechnology sector.
Related Filing Alerts
Source: Northern Trust's 13F filing on $ARWR (May 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Northern Trust 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts